scholarly journals The effects of fibronectin on the adhesion and migration of chinese hamster ovary cells on collagen substrata

1981 ◽  
Vol 49 (1) ◽  
pp. 299-310 ◽  
Author(s):  
S.L. Schor ◽  
A.M. Schor ◽  
G.W. Bazill

Data are presented indicating that the adhesion of Chinese hamster ovary cells (CHO) to films of denatured type I collagen occurs by a fibronectin-dependent mechanism, whereas the adhesion of these cells to 3-dimensional gels of native type I collagen fibres may occur by either a rapid, fibronectin-dependent mechanism or by a slower, fibronectin-independent mechanism, whereas the adhesion of these cells to 3-dimensional gels of native type I collagen fibres may occur by either a rapid, fibronectin-dependent mechanism or by a slower, fibronectin-independent mechanism. Data are also presented indicating that fibronectin promotes the migration of CHO cells on native type I collagen fibres.

1980 ◽  
Vol 46 (1) ◽  
pp. 171-186 ◽  
Author(s):  
S.L. Schor ◽  
T.D. Allen ◽  
C.J. Harrison

Three dimensional gels of native type I collagen fibres have been used as a substratum for the growth and migration of Chinese hamster ovary cells (fibroblastoid cell line) and RPMI-3460 melanoma cells (tumorigenic cell line from Syrian hamster). Quantitative data concerning the migration of these cells from the gel surface into the 3-dimensional collagen gel matrix have been obtained. The migration of both cell types into the collagen gel matrix is not accompanied by the degradation of collagen fibres. The possible implications of these observations for tumour cell invasion in vivo are discussed.


2002 ◽  
Vol 367 (1) ◽  
pp. 301-306 ◽  
Author(s):  
Victor D.H. DING ◽  
Sajjad A. QURESHI ◽  
Deborah SZALKOWSKI ◽  
Zhihua LI ◽  
Dawn E. BIAZZO-ASHNAULT ◽  
...  

Insulin regulates cellular metabolism and growth through activation of insulin receptors (IRs). We recently identified a non-peptide small-molecule IR activator (compound 2), which induced human IR tyrosine kinase activity in Chinese-hamster ovary cells expressing human IR [Qureshi, Ding, Li, Szalkowski, Biazzo-Ashnault, Xie, Saperstein, Brady, Huskey, Shen et al. (2000) J. Biol. Chem. 275, 36590—36595]. Oral treatment with this compound resulted in correction of hyperglycaemia, hypertriacylglycerolaemia and hyperinsulinaemia in several rodent models of diabetes. In the present study, we have found that this compound increased tyrosine phosphorylation of the IR β-subunit and IR substrate 1 in primary rat adipocytes as well as induced phosphorylation of Akt, the 70kDa ribosomal protein S6 kinase and glycogen synthase-3 (deactivation) in Chinese-hamster ovary cells expressing human IR. Similar to insulin, compound 2 stimulated glucose uptake, glycogen synthesis and inhibited isoprenaline-stimulated lipolysis in adipocytes. A structurally related analogue (compound 3) was devoid of the above activities suggesting that the activity of compound 2 is specifically mediated by targeted IR activation. The effects of compound 2 on stimulation of glucose uptake, glycogen synthesis and inhibition of lipolysis were blocked by wortmannin, consistent with the involvement of a phosphoinositide 3-kinase-dependent pathway. In addition, compound 2, but not compound 3, exhibited additive or synergistic effects with sub-maximal concentrations of insulin in rat adipocytes. Thus the IR activator was capable of activating insulin-mediated signalling and metabolic pathways in primary adipocytes. These results demonstrate that IR activators have implications for the future development of new therapeutic approaches to Type I and Type II diabetes.


1997 ◽  
Vol 272 (28) ◽  
pp. 17367-17375 ◽  
Author(s):  
Florence De Smedt ◽  
Ludwig Missiaen ◽  
Jan B. Parys ◽  
Valérie Vanweyenberg ◽  
Humbert De Smedt ◽  
...  

Pathology ◽  
1993 ◽  
Vol 25 (3) ◽  
pp. 268-276 ◽  
Author(s):  
Wanda B. Mackinnon ◽  
Marlen Dyne ◽  
Rebecca Hancock ◽  
Carolyn E. Mountford ◽  
Adrienne J. Grant ◽  
...  

Author(s):  
Shazid Md. Sharker ◽  
Md. Atiqur Rahman

Most of clinical approved protein-based drugs or under in clinical trial have a profound impact in the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to upgrade specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will concentrate on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.


Sign in / Sign up

Export Citation Format

Share Document